Section Edited by Howard L. Kaufman, MD, FACS
This section focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Research describing the characterization and basic biology of oncolytic agents and novel delivery systems are encouraged. An emphasis on how novel intra-tumoral directed agents modulate local and systemic host innate and adaptive anti-tumor immunity are of particular interest. In addition, the section welcomes translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens.
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapyChristianne Groeneveldt, Priscilla Kinderman, Jordi J C van Stigt Thans, Camilla Labrie, Lisa Griffioen, Marjolein Sluijter, Diana J M van den Wollenberg, Rob C Hoeben, Joke M M den Haan, Sjoerd H van der Burg, Thorbald van Hall, Nadine van Montfoort
19 July 2022
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockadeWon Suk Lee, Dong Sung Kim, Jeong Hun Kim, Yoonki Heo, Hannah Yang, Eun-Jin Go, Jin Hyoung Kim, Seung Joon Lee, Byung Cheol Ahn, Jung Sun Yum, Hong Jae Chon, Chan Kim
28 June 2022
BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanomaMirela Kremenovic, Alfred A Chan, Bing Feng, Lukas Bäriswyl, Steve Robatel, Thomas Gruber, Li Tang, Delphine J Lee, Mirjam Schenk
22 June 2022
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicityBeatrice Thier, Fang Zhao, Simone Stupia, Alicia Brüggemann, Johannes Koch, Nina Schulze, Susanne Horn, Christoph Coch, Gunther Hartmann, Antje Sucker, Dirk Schadendorf, Annette Paschen
13 June 2022
Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockadeFei Ju, Yong Luo, Chaolong Lin, Xian Jia, Zilong Xu, Rui Tian, Yanhua Lin, Min Zhao, Yating Chang, Xiaoxuan Huang, Shaopeng Li, Wenfeng Ren, Yaning Qin, Mengqin Yu, Jizong JiaSee the full list of authors
10 June 2022
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapyXiaoyi Jiang, Jian Wang, Xichen Zheng, Zhida Liu, Xinyu Zhang, Yuwei Li, Jonathan Wilhelm, Jun Cao, Gang Huang, Jinlan Zhang, Baran Sumer, Jayanthi Lea, Zhigang Lu, Jinming Gao, Min Luo
27 May 2022
Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumorsYinghan Su, Jiang Li, Weidan Ji, Gang Wang, Lin Fang, Qin Zhang, Lin Ang, Min Zhao, Yuan Sen, Lei Chen, Junnian Zheng, Changqing Su, Lunxiu Qin
24 May 2022
Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastomaTaylor J Aiken, Amy K Erbe, Lauren Zebertavage, David Komjathy, Arika S Feils, Matthew Rodriguez, Ashley Stuckwisch, Stephen D Gillies, Zachary S Morris, Jen Birstler, Alexander L Rakhmilevich, Paul M Sondel
20 May 2022
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapyMiriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y Bartee, Eric Bartee
16 May 2022
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib studyChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao YanSee the full list of authors
5 April 2022